| Drug General Information |
| Drug ID |
D0J7CE
|
| Former ID |
DIB016480
|
| Drug Name |
CDE-6960
|
| Synonyms |
CDE-6960; Protein kinase C epsilon/theta inhibitors (inflammation); PKC epsilon/theta inhibitors (inflammation), Devgen; Protein kinase C epsilon/theta inhibitors (inflammation), Devgen
|
| Indication |
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25]
|
Terminated |
[1]
|
|---|
| Company |
Devgen NV
|
| Target and Pathway |
| Target(s) |
Protein kinase C, epsilon type |
Target Info |
Inhibitor |
[2]
|
|---|
| Protein kinase C, theta type |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Tight junction
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Inflammatory mediator regulation of TRP channels
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cancerhsa04064:NF-kappa B signaling pathway
|
|
T cell receptor signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Measles
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Alzheimer disease-amyloid secretase pathway
|
|
Angiogenesis
|
|
Apoptosis signaling pathway
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
VEGF signaling pathway
|
|
Wnt signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Histamine H1 receptor mediated signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Thyrotropin-releasing hormone receptor signaling pathway
|
|
CCKR signaling map STP00003:Alzheimer disease-amyloid secretase pathway
|
|
T cell activation
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Endothelins
|
|
LPA receptor mediated events
|
|
TCR signaling in naï
|
|
LPA4-mediated signaling events
|
|
CDC42 signaling events
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL8- and CXCR1-mediated signaling events
|
|
Regulation of Ras family activation
|
|
Downstream signaling in naï
|
|
Endothelins
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Reactome
|
Effects of PIP2 hydrolysis
|
|
DAG and IP3 signaling
|
|
Role of phospholipids in phagocytosis
|
|
G alpha (z) signalling eventsR-HSA-111465:Apoptotic cleavage of cellular proteins
|
|
Inactivation, recovery and regulation of the phototransduction cascade
|
|
FCERI mediated NF-kB activation
|
|
G alpha (z) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Calcium Regulation in the Cardiac Cell
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
G Protein Signaling Pathways
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Oncostatin M Signaling Pathway
|
|
miRs in Muscle Cell Differentiation
|
|
GPCR downstream signaling
|
|
Effects of PIP2 hydrolysis
|
|
Physiological and Pathological Hypertrophy of the HeartWP69:TCR Signaling Pathway
|
|
Insulin Signaling
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Corticotropin-releasing hormone
|
|
Signaling Pathways in Glioblastoma
|
|
TCR signaling
|
|
Netrin-1 signaling
|
|
Apoptotic execution phase
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002) |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002) |
|---|
